NIH R01 · 2025
Targeting the cancer glycocalyx
PROJECT SUMMARY Altered cell-surface glycosylation is recognized as a hallmark of cancer. Two frequently observed cancer- associated glyco-phenotypes are hypersialylation and mucin overexpression. These cancer glycosylation patterns strongly correlate with disease aggressiveness and poor patient outcomes, but until recently their functional significance was unclear. In previous funding periods, we discovered that hypersialylation allows cancer cells to evade immune surveillance through engagement of immune inhibitory Siglec receptors. We speculate that poor responses of cancer patients to current immune therapies, including monoclonal antibodies, T cell checkpoint receptor blockade,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.